Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough.

Annexon Inc (ANNX) reports fourth-quarter 2025 earnings on March 30, 2026, with analysts expecting continued losses as the clinical-stage biopharmaceutical company advances its pipeline of complement-targeting therapies. The central question is whether management can demonstrate progress in its clinical programs while managing cash burn—a critical balance for a pre-revenue biotech trading at $5.00 per share with Wall Street's mean price target implying nearly 200% upside.

Part 1: Earnings Preview

Annexon Inc is a clinical-stage biopharmaceutical company developing complement-targeting therapies for autoimmune and neurodegenerative diseases, with lead programs targeting conditions including Guillain-Barré syndrome and Huntington's disease. The company's pipeline represents a high-risk, high-reward opportunity for investors betting on novel therapeutic approaches in areas of significant unmet medical need.

Annexon is scheduled to report fourth-quarter 2025 results on March 30, 2026. Analysts expect an EPS loss of $0.32 on consensus estimates from four analysts, with a range from -$0.36 to -$0.29. The company most recently reported a loss of $0.37 per share for the third quarter of 2025. Compared to the same quarter last year (Q4 2024), when ANNX posted a loss of $0.33 per share, the current estimate represents a 3.03% improvement year-over-year—a modest narrowing of losses that suggests the company is making incremental progress toward financial efficiency.

Three key themes define this earnings story:

Clinical Pipeline Advancement: Investors will scrutinize updates on Annexon's lead programs, particularly any data readouts or enrollment milestones that could validate the company's complement inhibition platform and justify its current valuation.

Cash Runway and Burn Rate: With no product revenue, the company's quarterly cash consumption and remaining runway are critical metrics. Any guidance on extending the cash runway through partnerships, non-dilutive financing, or operational efficiencies will be closely watched.

Regulatory Pathway Clarity: As programs advance through clinical stages, investors need visibility into regulatory strategies and timelines that could accelerate paths to approval and commercialization.

Analyst commentary ahead of the release remains constructive on the long-term opportunity, with the overwhelming majority maintaining buy ratings despite near-term losses. The focus is squarely on clinical execution and capital management rather than quarterly financial performance.

Part 2: Historical Earnings Performance

Annexon has demonstrated an inconsistent earnings track record over the past four quarters, with three misses and one modest beat. The company missed estimates by 17.86% in Q4 2024, followed by a significant 23.33% miss in Q1 2025—the worst performance in the recent period. Q2 2025 provided a brief respite with a 5.56% beat, but Q3 2025 returned to negative territory with an 8.82% miss.

The pattern reveals volatility in the company's ability to control expenses relative to analyst expectations, which is typical for clinical-stage biotechs where R&D spending can fluctuate based on trial timelines and enrollment rates. The magnitude of misses in Q4 2024 and Q1 2025 suggests analysts may have been too optimistic about expense management during those periods, while the Q2 beat indicates occasional quarters where spending comes in lighter than projected.

With the upcoming quarter's estimate calling for a loss of $0.32—slightly better than the $0.33 loss in the year-ago quarter—investors should approach with measured expectations. The recent miss in Q3 2025 and the company's three-out-of-four miss rate suggest risk is tilted toward another disappointment if clinical trial expenses or operational costs run higher than the Street anticipates.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Annexon typically reports earnings during market hours or after market close, meaning Day 0 captures either immediate intraday reaction or anticipation, while Day +1 reflects the first full trading session response.

Historical price behavior shows moderate volatility around earnings releases, with an average absolute Day 0 move of 5.49% and Day +1 move of 3.32%. The stock has exhibited mixed directional bias, with notable swings in both directions—the largest being a 13.52% surge on Day +1 following the March 2024 report, which saw an 18.02% intraday range.

Recent quarters show more contained reactions: the November 2025 report produced a modest 3.47% gain on Day 0, while August 2025 saw an 8.46% decline. The average Day 0 range of 8.32% and Day +1 range of 9.35% indicate investors should prepare for meaningful intraday volatility regardless of direction. For a clinical-stage biotech, these moves are relatively measured compared to peers, suggesting the market has become somewhat desensitized to quarterly financial results and is more focused on clinical catalysts and pipeline updates that may or may not coincide with earnings releases.

Part 2.2: Options Market Expected Move

The options market is pricing a 16.73% expected move through the April 17 expiration—substantially higher than the historical average Day 0 move of 5.49% and even exceeding the average Day +1 move of 3.32%. This elevated implied volatility suggests options traders are anticipating either significant news beyond routine quarterly results or heightened uncertainty around clinical updates that could accompany the earnings release.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Annexon, with the consensus rating at 4.73 out of 5.0—firmly in Strong Buy territory. The breakdown shows 9 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with zero sell ratings across the 11 analysts covering the stock. This lopsided positive sentiment reflects confidence in the company's long-term clinical and commercial potential despite near-term losses.

The mean price target of $14.71 implies 194% upside from the current price of $5.00, with a wide range spanning from a low of $8.00 (60% upside) to a high of $27.00 (440% upside). This broad dispersion reflects the binary nature of clinical-stage biotech investing, where outcomes are heavily dependent on trial results and regulatory decisions.

Analyst sentiment has remained unchanged over the past month, with ratings distribution and the average recommendation holding steady at 4.73. This stability suggests analysts are maintaining conviction in their bullish thesis while awaiting clinical catalysts rather than reacting to recent stock price movements. The lack of downgrades despite the stock trading well below most price targets indicates the Street views current levels as an attractive entry point for risk-tolerant investors willing to bet on pipeline success.

Part 4: Technical Picture

The Barchart Technical Opinion currently registers a 24% Buy signal, representing a significant deterioration from 40% Buy both one week and one month ago. This weakening technical picture suggests momentum has faded heading into the earnings release, with the stock struggling to maintain bullish conviction.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates near-term momentum has stalled, with the stock lacking clear directional bias in the immediate trading sessions
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate-term trend remains cautiously constructive despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects a balanced longer-term outlook, with the stock maintaining support above key long-term averages

Trend Characteristics: The trend is characterized as Weak with Weakest direction, indicating deteriorating momentum and vulnerability heading into the earnings event.

The stock is trading at $5.00, positioned below its 5-day ($5.20), 10-day ($5.33), 20-day ($5.46), 50-day ($5.67), and 100-day ($5.05) moving averages—a bearish configuration across all short- and intermediate-term timeframes. However, ANNX remains above its 200-day moving average of $3.84, providing a critical long-term support level and confirming the stock has maintained gains from earlier in the trend. The technical setup is cautionary heading into earnings, with the stock breaking below multiple near-term support levels and showing weakening momentum. Investors should be prepared for heightened volatility, and the breach of short-term moving averages suggests limited technical support until the 200-day average near $3.84. A positive earnings surprise or clinical update would need to be substantial to reverse the current technical deterioration.